In Sync: Simultaneous Prescription Refills Boosts Medication Adherence, Penn Study Shows
Synchronized Prescription Refill Programs Help Reduce Obstacles to Adherence and Improve Adherence in Some Patients by More than 10 Percent
Newswise — PHILADELPHIA – Programs aimed at helping patients adhere to prescription medication regimens have become an area of interest for researchers as nearly half of patients do not take medications as prescribed. In a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania and Humana Inc. show that a refill synchronization program – in which patients were able to receive all refills at the same time – increased medication adherence by more than 10 percent in some patient subgroups. The results are published today in Health Affairs.
“The logistical challenges involved with keeping track of remaining pills and obtaining timely refills and renewals are magnified for patients who need to take multiple medications, and often create an obstacle to medication adherence,” said lead author Jalpa A. Doshi, PhD, an associate professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, and director of Value-Based Insurance Design Initiatives in Penn’s Center for Health Incentives and Behavioral Economics. “Based on the results of our study, synchronized prescription programs that adjust medication refill dates so that all prescriptions are ‘due’ for a refill at the same time may be an effective strategy to reducing these obstacles.”
Though medication synchronization programs have been widely adopted and are currently available at nearly two dozen pharmacy chains and more than 2,000 independent pharmacies in the United States, to date, there has been a lack of research on the effectiveness of these programs.
In the study, 691 Medicare patients receiving two to six oral medications for high blood pressure, high cholesterol, or diabetes via a mail-order pharmacy, were enrolled in a synchronized refill program in which pharmacists adjusted their prescription schedules so all medications would be eligible for refill on the same day. Medication adherence was tracked for a period of 12 months before and after enrollment into the synchronized refilled program and compared to a control group of 695 Medicare patients who received “usual care” from their mail-order pharmacy, which included automated reminders about refills but did not synchronize prescription schedules.
On average, patients enrolled in the synchronized refill program increased medication adherence by three to five percent over the control group, an increase in adherence rates comparable to other widely adopted improvement approaches such as value-based insurance designs. Of particular interest, researchers noted that refill synchronization had even larger effects among patients who had the lowest levels of adherence before the intervention. In this group, patients improved adherence by nine to 13 percent over the control group.
“Previous research has shown a direct correlation between medication adherence and improved health outcomes, but future studies are needed to examine whether synchronized refill programs are associated with changes in health outcomes, as well as the economic impact of such programs,” said senior author Kevin Volpp, MD, PhD, a professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania and director of Penn’s Center for Health Incentives and Behavioral Economics.
Though synchronization targets and removes several of the logistical obstacles related to obtaining a regular medication supply to facilitate medication adherence, researchers note that prescription refill synchronization alone is not able to target other common causes of nonadherence, such as forgetting doses or ambivalence to taking medications. “Nevertheless, prescription synchronization can be combined with other types of interventions, based on a patient’s specific adherence challenges to further enhance medication adherence,” said Doshi.
Other Penn authors include Raymond Lim, Pengxiang Li, and Andrea Troxel.
Support for the study was provided by Humana Inc.
Disclosure: Co-authors Peinie Young, Victor Lawnicki, and Joseph State are employees of and own stock in Humana Inc.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.